Chronic Leukemia

5

Review clinical trials related to Chronic Leukemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study

People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.

Participants needed: 75
Trial details
Age: 18-90Biological sex: AllType: ObservationalSponsor: University of AlbertaUpdated: May 11, 2026Locations: 1
Eligibility criteria

Not listed

Status: Recruiting

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.

Participants needed: 250
Trial details
Age: 1+Biological sex: AllType: InterventionalSponsor: Azienda Ospedaliero-Universitaria di ParmaUpdated: Mar 3, 2026Locations: 1
Eligibility criteria

Patient aged >1 year old, referred for evaluation to the University Hospital of... [+3]

Age <1 year old [+1]

Status: Recruiting

Feasibility of a Multi-omics Platform for Hematological Malignancies

This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleural effusion.

Participants needed: 1,040
Trial details
Age: 2+Biological sex: AllType: InterventionalSponsor: Azienda Ospedaliero-Universitaria di ParmaUpdated: Mar 3, 2026Locations: 1
Eligibility criteria

Patient aged > 2 year old [+4]

Age <2 year old [+1]

Status: Recruiting

INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)

This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.

Participants needed: 300
Trial details
Age: 1+Biological sex: AllType: InterventionalSponsor: Azienda Ospedaliero-Universitaria di ParmaUpdated: Feb 17, 2026Locations: 2
Eligibility criteria

Patients aged one year and over who are referred to the centres involved in the... [+3]

Patients younger than 1 year old [+1]

Status: Recruiting

Umbilical Cord Blood Transplantation From Unrelated Donors

This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-free survival and the rate of relapse (a return of your disease or syndrome) as well as the incidence and severity of graft versus host disease (GvHD) following cord blood stem cell transplantation. GvHD is a complication of stem cell transplants in which white blood cells from the transplanted tissue (graft) attack the transplant recipient's body (host).

Participants needed: 30
Trial details
Age: 2-75Biological sex: AllType: ObservationalSponsor: University of RochesterUpdated: Oct 10, 2025Locations: 1
Eligibility criteria

Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldri... [+31]

Availability of 10/10 or 9/10 HLA-matched related or unrelated donor within a re... [+4]